What Is eCTD Software? A Complete Guide for Regulatory Submissions
Regulatory submissions in the pharmaceutical and life sciences industry should be done under stringent world standards. The regulatory bodies in most countries of the world demand that the companies provide huge amounts of paperwork in regard to the development of drugs, clinical trials, and quality of the products.
What is Quality Assurance (QA) in Pharma?
Quality Assurance (QA) is a critical component of the pharmaceutical industry that ensures medicines are consistently developed, manufactured, and distributed according to established quality standards. Pharmaceutical products must meet strict regulatory and safety requirements before reaching patients.
What is an IND Application (Investigational New Drug Application)
In the pharmaceutical industry, new drugs must undergo rigorous evaluation before they can be tested in humans. One of the most important regulatory steps in this process is the Investigational New Drug Application (IND). The IND allows pharmaceutical companies to begin clinical trials and ensures that investigational drugs are safe enough for human testing while protecting study participants.
Responding to FDA Form 483 Observations After a Drug CGMP Inspection
Regulatory checks are very essential in the aspect of making sure that pharmaceutical producers are adhering to the existing requirements of Good Manufacturing Practice (CGMP). In an inspection, U.S. Food and drug administration (FDA) might find conditions that may be against regulatory provisions. Such results are reported in the FDA Form. 483 – Inspectional Observations.
Understanding the FDA Draft Guidance on Biosimilar Development and the BPCI Act (Revision 4)
The U.S. Food and Drug Administration (FDA) released New and Revised Draft Q&As on Biosimilar Development and the BPCI Act (Revision 4) in March 2026 to clarify regulatory expectations for biosimilar and interchangeable biological products.